The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Mavyret (glecaprevir and pibrentasvir)

Are there any other warnings one should know regarding Mavyret?

Risk of Hepatitis B Reactivation

The FDA has indicated that there is risk of the Hepatitis B virus becoming an active infection again in any patient who has a current or previous infection with Hepatitis B virus and is being treated with Mavyret, a direct-acting antiviral medicine for Hepatitis C virus. In a few cases, Hepatitis B virus reactivation in patients treated with these types of medicines resulted in serious liver problems or death. In addition to a prominent warning being required on the medication’s labeling, healthcare professionals are being directed to also screen and monitor for the Hepatitis B virus in all patients receiving this treatment.

Last Updated: October 2017

"FDA approves Mavyret for Hepatitis C." FDA.gov. U.S. Food & Drug Administration. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm. Retrieved October 6, 2017.

"Highlights of Prescribing Information." Rxabbvie.com. AbbVie Inc., http://www.rxabbvie.com/pdf/mavyret_pi.pdf. Retrieved October 6, 2017.

"Mavyret Product Summary." Mavyret.com. AbbVie Inc., https://www.mavyret.com/content/dam/abbvie-mavyret-brand/product-summary.pdf. Retrieved October 6, 2017.

"Introducing MavyRet." Mavyret.com. AbbVie Inc., www.mavyret.com. Retrieved October 6, 2017.